Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a 403 Forbidden error page state with basic HTML boilerplate, indicating access is blocked; the surrounding site chrome remains visible, meaning this is an access issue rather than a content update.SummaryDifference17%

- Check35 days agoChange DetectedThe page now shows a new revision tag indicating a minor update to the page version. No changes to the study details or eligibility criteria are evident from this update.SummaryDifference0.1%

- Check50 days agoChange DetectedResults status updated from 'No Results Posted' to 'Results Submitted'. This indicates that the trial results have been prepared and submitted for posting.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5, indicating a new version of the page content. This change is a metadata update and does not modify the study details or user-facing information.SummaryDifference0.1%

- Check71 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, signaling a minor frontend update to the study details page.SummaryDifference0.1%

- Check93 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, indicating a small maintenance update to the page rather than changes to study details.SummaryDifference0.1%

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.